CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Hunan Fangsheng Pharmaceutical Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Hunan Fangsheng Pharmaceutical Co Ltd
No.19 Lutian Road, Lugu, Hexi
Phone: +86 73188997135p:+86 73188997135 CHANGSHA, HUN  410205  China Ticker: 603998603998
Business Summary
Hunan Fangsheng Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company primarily operates its businesses through two segments. The Pharmaceutical Manufacturing Business segment mainly provides cardiovascular and cerebrovascular drugs, orthopedic drugs, respiratory drugs, pediatric drugs, gynecological drugs and anti-infective drugs. The Company's main products include Xuesetong dispersible tablets, Xuesetong tablets, Garcinia bone-strengthening tablets, Dieda Huoxue capsules, Lysine Vitamin B12 granules, Cefuroxime tablets, Jinying capsules, Pudilan anti-inflammatory tablets, Xiaoer Jingxing cough granules, Ezetimibe tablets, Xuanqi bone-strengthening tablets, Qiangli Loquat Paste (honey-refined), Qiangli Loquat Dew and others. The Others segment is mainly engaged in other businesses such as medical services, pharmaceutical commerce and drug sales.
(Source: F-4)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
5122 Drugs, drug proprietaries, and druggists' sundries
8062 General medical and surgical hospitals
8731 Commercial physical and biological research
0139 Field crops, except cash grains, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, General Manager XiaoliZhou 50 3/6/2022 3/6/2022
Vice Chairman of the Board Yuan MingTan 43 7/6/2015 7/6/2015
Deputy General Manager, Director BoChen 36 7/6/2015 7/6/2015
6 additional Officers and Directors records available in full report.

General Information
Number of Employees: 1,686 (As of 12/31/2023)
Outstanding Shares: 439,120,060 (As of 9/30/2024)
Shareholders: 26,535
Stock Exchange: SHA
Fax Number: +86 73188908647


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024